CO5640129A2 - Agonistas del receptor activado por proliferador de peroxisoma - Google Patents

Agonistas del receptor activado por proliferador de peroxisoma

Info

Publication number
CO5640129A2
CO5640129A2 CO04049275A CO04049275A CO5640129A2 CO 5640129 A2 CO5640129 A2 CO 5640129A2 CO 04049275 A CO04049275 A CO 04049275A CO 04049275 A CO04049275 A CO 04049275A CO 5640129 A2 CO5640129 A2 CO 5640129A2
Authority
CO
Colombia
Prior art keywords
alkyl
group
substituted
unsubstituted
aryl
Prior art date
Application number
CO04049275A
Other languages
English (en)
Spanish (es)
Inventor
Tracey Ann Gibson
Johnston Richard Duane
Nathan Bryan Mantlo
Richard Craig Thompson
Xiaodong Wang
Leonard Larry Winneroski
Yanping Xu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5640129A2 publication Critical patent/CO5640129A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CO04049275A 2001-11-30 2004-05-27 Agonistas del receptor activado por proliferador de peroxisoma CO5640129A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33445301P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
CO5640129A2 true CO5640129A2 (es) 2006-05-31

Family

ID=23307275

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04049275A CO5640129A2 (es) 2001-11-30 2004-05-27 Agonistas del receptor activado por proliferador de peroxisoma

Country Status (19)

Country Link
US (1) US7544812B2 (enExample)
EP (1) EP1453811A2 (enExample)
JP (1) JP2005517643A (enExample)
KR (1) KR20050044606A (enExample)
CN (1) CN1582279A (enExample)
AU (1) AU2002356927A1 (enExample)
BR (1) BR0214437A (enExample)
CA (1) CA2468846A1 (enExample)
CO (1) CO5640129A2 (enExample)
EA (1) EA007163B1 (enExample)
HR (1) HRP20040469A2 (enExample)
HU (1) HUP0402486A3 (enExample)
IL (1) IL161578A0 (enExample)
MX (1) MXPA04005123A (enExample)
NO (1) NO20042737L (enExample)
NZ (1) NZ532909A (enExample)
PL (1) PL370515A1 (enExample)
WO (1) WO2003048130A2 (enExample)
ZA (1) ZA200404173B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1662487A (zh) 2002-06-19 2005-08-31 伊莱利利公司 酰胺连接基过氧化物酶体增殖物激活受体调节剂
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
DE10351859A1 (de) * 2003-11-06 2005-06-09 Beiersdorf Ag Emulsionen mit zwei Verdickungsmitteln
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
WO2006036512A2 (en) * 2004-09-28 2006-04-06 Allergan, Inc. Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
CA2655574A1 (en) 2006-06-20 2007-12-27 Wyeth Imidazole kv1.5 potassium channel inhibitors
FR2903984B1 (fr) * 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
WO2008094860A2 (en) 2007-01-30 2008-08-07 Allergan, Inc. Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
CN101875636B (zh) * 2010-05-18 2012-01-04 浙江大学 咪唑啉-2,4-二酮类衍生物及制备方法和用途
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
CN115894379B (zh) * 2022-01-20 2025-06-27 哈尔滨三联药业股份有限公司 海因类化合物及其医药用途
CN114835655A (zh) * 2022-04-14 2022-08-02 河南师范大学 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法
LU605402B1 (en) * 2024-07-11 2026-07-14 Sea4Us Biotecnologia E Recursos Marinhos Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452041A (en) * 1965-05-19 1969-06-24 American Home Prod Hydantoin compounds and methods of preparation
HU183046B (en) 1976-06-03 1984-04-28 Wellcome Found Process for producing hydanthoine derivatives
GB1601310A (en) 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS59159163A (ja) * 1983-03-01 1984-09-08 Fuji Photo Film Co Ltd ハロゲン化銀カラ−感光材料
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
PT966447E (pt) 1997-03-03 2003-07-31 Boehringer Ingelheim Pharma Moleculas pequenas uteis no tratamento de doencas inflamatorias
WO2001016120A1 (en) * 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators

Also Published As

Publication number Publication date
CA2468846A1 (en) 2003-06-12
US7544812B2 (en) 2009-06-09
WO2003048130A2 (en) 2003-06-12
HRP20040469A2 (en) 2004-10-31
EP1453811A2 (en) 2004-09-08
HUP0402486A2 (hu) 2005-03-29
JP2005517643A (ja) 2005-06-16
NO20042737L (no) 2004-08-17
CN1582279A (zh) 2005-02-16
HUP0402486A3 (en) 2007-05-02
ZA200404173B (en) 2005-08-23
NZ532909A (en) 2006-08-31
PL370515A1 (en) 2005-05-30
BR0214437A (pt) 2004-10-13
MXPA04005123A (es) 2005-02-17
WO2003048130A3 (en) 2003-11-20
EA200400748A1 (ru) 2004-12-30
IL161578A0 (en) 2004-09-27
US20050020652A1 (en) 2005-01-27
AU2002356927A1 (en) 2003-06-17
EA007163B1 (ru) 2006-08-25
KR20050044606A (ko) 2005-05-12

Similar Documents

Publication Publication Date Title
PE20020693A1 (es) Agonistas del receptor alfa activado del proliferador de peroxisomas
PE20071022A1 (es) Compuestos derivados de dibencilamina como inhibidores de la proteina de transferencia del colesteril ester (cept)
AR046244A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
MY102027A (en) Leukotriene antagonists
ECSP045121A (es) Agonistas del receptor activado por proliferador de peroxisoma
PE20010964A1 (es) Derivados de tiazolilamida
CO4940472A1 (es) Pirazolopirimidonas para la disfuncion sexual
CO5601013A2 (es) Compuestos que modulan la actividad de ppar
PE20030199A1 (es) Derivados de n-[benzoil]-fenilsulfonamida
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
ES2546851T3 (es) Inhibidores de fosfatidilinositol 3-cinasa
CY1105899T1 (el) Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες
NO20062031L (no) Derivater av N-[fenyl(alkylptpertdtn-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske media
AR046615A1 (es) Pirrolidinas 3-(benzoil)-n-aciladas, como inhibidores de 11-beta-hsd1, utiles en el tratamiento de desordenes metabolicos
PE20010628A1 (es) Compuestos de amina ciclica, su produccion y su uso
ES2193990T3 (es) Derivados de purina.
HRPK20040930B3 (en) Acyl-4-carboxyphenylurea derivatives, method for production and use thereof
AR015512A1 (es) Derivados ciclicos n-acilo amina, un procedimiento para su preparacion, un intermediario y una composicion farmaceutica
CO4700453A1 (es) N-(INDOL-2-CARBONIL)-beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO AGENTES ANTIDIABETICOS
IL87795A (en) Benzimidazolin-2-oxo- 1-carboxylic acid ester and amide derivatives, their preparation and pharmaceutical compositions containing them
CO5011090A1 (es) Derivados de acil-piperazinil-pirimidinas, procedimiento para su preparacion y composiciones farmaceuticas de los mismos
PE20080429A1 (es) Analogos de piperidina, morfolina y pirrolidinilo
PE20011212A1 (es) Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
EA200400748A1 (ru) Агонисты рецепторов, активируемых пероксисомным пролифератором

Legal Events

Date Code Title Description
FA Application withdrawn